GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it…
23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6…
Ad hoc announcement pursuant to Art. 53 LR Medtronic deal accounted in 2024, to inject USD 200m cash. FDA approval…
Notice of Allowance for Significant POLB 001 Patent in United StatesNotice of Allowance for Immunomodulator II further strengthens robust intellectual…
New application provides additional support to patients and caregivers from the homeMORRISVILLE, N.C.--(BUSINESS WIRE)--#caregiverapp--Spencer Health Solutions (SHS) announced today the…
CHICAGO, IL / ACCESSWIRE / March 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…
PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical…
- Update on the Phase 3 REGAL Clinical Trial of GPS in Acute Myeloid Leukemia (AML) - - Update on…
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage…
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development…